Tag Archives: Difei Yang

Nightstar Therapeutics Limited (NITE) Gets a Buy Rating from Mizuho Securities

Mizuho Securities analyst Difei Yang maintained a Buy rating on Nightstar Therapeutics Limited (NASDAQ: NITE) today and set a price target of $20. The company’s shares closed yesterday at $17.98. Yang wrote: “We expect upcoming data from the NSR-RPGR program,

Mizuho Securities Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Nektar Therapeutics (NASDAQ: NKTR) today and set a price target of $103. The company’s shares closed yesterday at $55.96. Yang observed: “We highlighted results in our previous note here. Nektar,

Selecta Biosciences (SELB) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Difei Yang maintained a Buy rating on Selecta Biosciences (NASDAQ: SELB) today and set a price target of $30. The company’s shares closed yesterday at $13.02. Yang wrote: “We do not see quarterly earnings as the most

Analysts Offer Insights on Healthcare Companies: Zogenix (NASDAQ: ZGNX), Spark Therapeutics (NASDAQ: ONCE) and Arqule (NASDAQ: ARQL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zogenix (NASDAQ:ZGNX), Spark Therapeutics (NASDAQ:ONCE) and Arqule (NASDAQ:ARQL). Zogenix (ZGNX) Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix today and set a

Spark Therapeutics (ONCE) Receives a Rating Update from a Top Analyst

Mizuho Securities analyst Difei Yang maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today. The company’s shares closed yesterday at $56.01. Yang wrote: “We further think it is pre-mature to draw the conclusion that SPK-8011 is inferior to the

Analyst Explains Why They Upgraded Their Rating on Audentes Therapeutics (BOLD)

In a report released today, Difei Yang from Mizuho Securities upgraded Audentes Therapeutics (NASDAQ: BOLD) to Buy, with a price target of $45. The company’s shares closed yesterday at $34.25. Yang wrote: “We do not see quarterly earnings as the